Claims
- 1-36. (Canceled)
- 37. A method for treating or preventing septic shock syndrome in a mammal, the method comprising administering to the mammal an effective amount of an antibody that binds native human tissue factor and does not substantially bind non-native tissue factor, wherein the Factor X or Factor 1× binding to the complex is inhibited and the administration is sufficient to prevent or treat the septic shock syndrome in the mammal.
- 38. The method of claim 37, wherein the antibody has the binding specificity for native human tissue factor about equal to or greater than H36.D2.B7 [ATCC HB-12255].
- 39. The method of claim 37, wherein the antibody is a monoclonal antibody.
- 40. The method of claim 37 wherein the antibody is a chimeric antibody.
- 41. The method of claim 40, wherein the antibody comprises a constant region of human origin.
- 42. The method of claim 37, wherein the antibody is a single chain antibody.
- 43. The method of claim 37, wherein the antibody comprises a sequence that has at least about 70 percent sequence identity to SEQ ID NO:1.
- 44. The method of claim 43, wherein the antibody comprises a sequence represented by SEQ ID NO:2 or SEQ ID NO:4.
- 45. The method of claim 37, wherein the antibody comprises hypervariable regions that have at least 90 percent sequence identity to SEQ ID NOS. 5 through 10 inclusive.
- 46. The method of claim 45, wherein the antibody comprises hypervariable regions represented by SEQ ID NOS. 5 through 10 inclusive.
- 47. The method of claim 37, wherein the antibody is humanized.
- 48. The method of claim 47, wherein the antibody is a humanized chimeric antibody.
- 49. The method of claim 47, wherein the antibody comprises human variable regions.
- 50. The method of claim 37 or 47, wherein the antibody is an immunologically active antibody fragment.
- 51. The method of claim 50, wherein the fragment is a Fab, F(v), Fab′ or F(ab)2 fragment.
- 52. The method of claim 37 or 47, wherein Factor X binding to the complex is inhibited by at least about 80 percent in a standard in vitro binding assay.
- 53. The method of claim 52, wherein the Factor X binding to the complex is inhibited by at least about 90 percent in a standard in vitro binding assay.
- 54. The method of claim 53, wherein the Factor X binding to the complex is inhibited by at least about 95 percent in a standard in vitro binding assay.
- 55. The method of claim 37, wherein the mammal is a human patient who has or is suspected of having septic shock syndrome.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of U.S. Ser. No. 10/293,417 as filed on Nov. 12, 2002, which application is a continuation of U.S. Ser. No. 09/293,854 as filed on Apr. 16, 1999 (now U.S. Pat. No. 6,555,319), which application is a continuation of U.S. Ser. No. 08/814,806 (now U.S. Pat. No. 5,986,065) as filed on Mar. 10, 1997. The disclosures of the U.S. Ser. No. 10/293,417 and U.S. Pat. Nos. 6,555,319 and 5,986,065 are incorporated herein by reference.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09293854 |
Apr 1999 |
US |
Child |
10293417 |
Nov 2002 |
US |
Parent |
08814806 |
Mar 1997 |
US |
Child |
09293854 |
Apr 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10293417 |
Nov 2002 |
US |
Child |
10764140 |
Jan 2004 |
US |